Advertisement
Advertisement
CNTX
Context Therapeutics Inc. Common Stock
0.19
USDSponsored
-0.01
-6.64%
Nov 10, 15:58 UTC -5
Closed
After-Market
0.20
+0.01
+6.42%
Context Therapeutics Inc. Common Stock (CNTX) Earnings
CNTX Earnings Reports
Positive Surprise Ratio
CNTX beat 9 of 18 last estimates.
50%
Next Report
Tomorrow
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.11
Implied change from Q2 26 (Revenue/ EPS)
--
/-26.67%
Implied change from Q3 25 (Revenue/ EPS)
--
/+10.00%
Context Therapeutics Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, CNTX reported earnings of -0.15 USD per share (EPS) for Q2 26, missing the estimate of -0.09 USD, resulting in a -59.40% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -27.27% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an decrease of -26.67% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Definium Therapeutics, Inc. Common Shares
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.56
Actual
-$0.46
Surprise
+19.06%
Ocular Therapeutix, Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.42
Surprise
-13.54%
Harrow, Inc. Common Stock
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.22
Actual
$0.12
Surprise
-45.92%
SIGA Technologies Inc.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-Actual
-$0.04
Surprise
-
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Tonix Pharmaceuticals Holding Corp.
Report Date
Nov 09, 2026 For Q3 26
Estimate
-$2.40
Actual
-$2.89
Surprise
-20.23%
Cumberland Pharmaceuticals Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
-$0.07
Surprise
-
PMV Pharmaceuticals, Inc
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.23
Actual
-$1.81
Surprise
-46.07%
FAQ
What were Context Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Context Therapeutics Inc. Common Stock reported EPS of -$0.15, missing estimates by -59.4%, and revenue of $0.00, 0% as expectations.
How did the market react to Context Therapeutics Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -27.27%, changed from $0.69 before the earnings release to $0.50 the day after.
When is Context Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Context Therapeutics Inc. Common Stock's next earnings report?
Based on --
analysts, Context Therapeutics Inc. Common Stock is expected to report EPS of -$0.11 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.